Testing the Safety of New Drugs for Glioblastoma That Has Come Back
Original title: Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to see if new drugs are safe in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This early study is testing whether some new drugs are safe for people whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back.
Who this trial is for. This study is for people whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back. It is testing the drugs ABBV-637 and ABBV-155, given alone or with another drug called ERAS-801.
Where it stands. This study is checking whether these drugs are safe. It is also looking at the side effects they cause and how mild they are. The trial has not reported any results yet.
What this means, and what it doesn't
What it could mean: If your glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back, this is one study that is testing new drugs. If you think you might fit, you can ask your care team about it. The trial team decides who can join.
What it doesn't mean: This trial is a test, not a proven treatment. We do not know yet if these drugs are safe or if they help. Being in a trial does not mean you will get better. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.